PMID- 10933119
OWN - NLM
STAT- MEDLINE
DCOM- 20010109
LR  - 20131121
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 10
IP  - 2
DP  - 2000 Summer
TI  - Efficacy and safety findings from naturalistic fluoxetine drug treatment in 
      adolescent and young adult patients.
PG  - 91-102
AB  - This article reports on the efficacy and safety of the selective serotonin 
      reuptake inhibitor, fluoxetine, in 213 patients (ages 11-23 years) treated by 
      psychiatrists/neurologists (PN) or general practitioners/internists (GPI). Data 
      were derived from naturalistic drug utilization observation (DUO) studies with 
      fluoxetine (n = 18,759 patients). Data collection--at the start and the end of 
      the observation period (< or =6 weeks)--included patient characteristics, 
      diagnoses, medication, co-medication, efficacy, and adverse events (AEs). 
      Nonparametric statistics and descriptive p values (two-tailed) were used. 
      Analyses revealed various differences between PN (n = 56) and GPI (n = 157) 
      samples as to patient and treatment characteristics (p < 0.001-0.08). Based on 
      both Clinical Global Impression (CGI; all p < 0.001) and self-assessment (total n 
      = 47; Zung SDS, all p < or = 0.003), both PN and GPI patients showed improvements 
      in their symptomatology over time, including suicidality (all p < 0.001; there 
      were no group differences). Overall AE rates were higher in PN patients (p < 
      0.01; 17.9% vs. 4.5%); the frequency and type of AEs in both subgroups were 
      typical for fluoxetine and the total DUO samples. In fact, AE rates were lower 
      compared to controlled trials. Findings suggest that PN patients were more 
      severely ill at observation start and suffered a more complicated treatment 
      course. However, clinical efficacy showed highly significant improvements in both 
      subgroups; AE rates were low in both--although higher in PN patients. Thus, 
      results support a positive benefit/risk ratio of fluoxetine use for this young 
      patient population.
FAU - Dittmann, R W
AU  - Dittmann RW
AD  - Psychosomatic Department, Children's Hospital, University of Hamburg, Germany. 
      DITTMANN_RALF_W@Lilly.com
FAU - Czekalla, J
AU  - Czekalla J
FAU - Hundemer, H P
AU  - Hundemer HP
FAU - Linden, M
AU  - Linden M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 01K63SUP8D (Fluoxetine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/*adverse effects/*therapeutic use
MH  - Child
MH  - Comorbidity
MH  - Depressive Disorder/*drug therapy/psychology
MH  - Drug Interactions
MH  - Female
MH  - Fluoxetine/*adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Psychiatric Status Rating Scales
MH  - Suicide/psychology
EDAT- 2000/08/10 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/10 11:00
PHST- 2000/08/10 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/10 11:00 [entrez]
AID - 10.1089/cap.2000.10.91 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2000 Summer;10(2):91-102. doi: 
      10.1089/cap.2000.10.91.